NCT05076617
A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Sep 26, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
The 50 most recent of 90 versions: 41 with changes below, 9 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites reduced: 136 → 133 locations
- Notable Eligibility criteria expanded, about 20 words
- Study sites: 137 to 136
- Secondary endpoints: details revised at 1 of 3 entries
- Minor Trial sites reduced: 140 → 137 locationsv89
- Minor Trial sites reduced: 146 → 140 locationsv88
- Minor Site details revised at 2 of 146 sitesv86
Show 37 earlier versionsHide 37 earlier versions
- Minor Study sites: 145 to 146v84
- Minor Study sites: 144 to 145v82
- Minor Study sites: 143 to 144v81
- Minor Study sites: 141 to 143v78
- Minor Study sites revised (141)v77
- Minor Site details revised at 2 of 141 sitesv76
- Minor Study sites: 139 to 141v75
- Minor Study sites: 140 to 139v74
- Study Status, Outcome Measures, Eligibilityv73
- Minor Study sites: 139 to 140v72
- Minor Study sites: 135 to 139v71
- Minor Study sites: 143 to 135v70
- Minor Study sites: 141 to 143v69
- Minor Study sites: 140 to 141v68
- Minor Study sites: 139 to 140v67
- Minor Study sites: 138 to 139v66
- Minor Study sites: 137 to 138v64
- Minor Study sites: 135 to 137v63
- Minor Study sites: 132 to 135v62
- Minor Study sites: 129 to 132v60
- Minor Study sites: 136 to 129v58
- Notable Primary and study completion dates: May 22, 2026 to Nov 30, 2028v57
- Minor Study sites: 135 to 136v56
- Minor Study sites: 134 to 135v54
- Minor Study sites: 133 to 134v53
- Minor Study sites: 137 to 133v52
- Minor Study sites: 136 to 137v51
- Minor Site details revised at 1 of 136 sitesv50
- Minor Site details revised at 1 of 136 sitesv49
- Minor Study sites: 138 to 136v48
- Minor Study sites: 139 to 138v47
- Minor Study sites: 138 to 139v46
- Minor Study sites: 137 to 138v45
- Minor Study sites: 139 to 137v44
- Minor Study sites: 138 to 139v43
- Minor Study sites: 137 to 138v42
- Minor Study sites: 135 to 137v41
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Frequency of treatment-emergent adverse events (TEAEs)
Timeframe: From Baseline up to the End of Study Visit (up to 78 months)
Frequency of TEAEs leading to withdrawal from study
Timeframe: From Baseline up to the End of Study Visit (up to 78 months)
Frequency of serious TEAEs
Timeframe: From Baseline up to the End of Study Visit (up to 78 months)
Secondary (3)
Treatment success after investigational medicinal product (IMP) administration for seizures occurring within the first 12 months
Treatment success after IMP administration with no recurrence after 2 hours for seizures during the first 12 months
Frequency of respiratory TEAEs
Arms and interventions
Staccato alprazolamExperimental
Participants will receive Staccato alprazolam by inhalation.
Drugs: Staccato alprazolam
Sites
133 sites in 12 countries
United States 45, China 25, Japan 18, Spain 8, Poland 6, Czechia 5, Germany 5, Italy 5, United Kingdom 5, Bulgaria 4, Hungary 4, Australia 3